Last updated: February 23, 2026
What is NDC 13668-0008?
NDC 13668-0008 is a biosimilar version of a branded biologic. Based on available data, it is identified as a biosimilar to Herceptin (trastuzumab). This biologic is used primarily for HER2-positive breast cancer, gastric cancer, and other HER2-overexpressing tumors.
Market Size and Demand Drivers
Market Size
The global trastuzumab market was valued at approximately $9 billion in 2022 and is projected to reach $12 billion by 2027, growing at a CAGR of around 5.8%. Biosimilars like NDC 13668-0008 are responsible for a rising share due to patent expirations of originator biologics.
Key Demand Factors
- Patent expiry: Herceptin's main patents expired in the U.S. in 2019, enabling biosimilar entry.
- Pricing pressure: Biosimilars are priced 15-30% lower than originators.
- Policy incentives: Governments and payers promote biosimilar adoption to reduce healthcare costs.
- Clinical acceptance: Increasing confidence among physicians regarding biosimilars' equivalence.
Regional Market Trends
| Region |
2022 Market Share |
Expected Growth (2023-2027) |
Key Drivers |
| North America |
45% |
6% CAGR |
Patents expired, reimbursement |
| Europe |
35% |
7% CAGR |
Strong biosimilar policies |
| Asia-Pacific |
15% |
9% CAGR |
Rising cancer incidence, affordability |
Competitors
Major biosimilars of trastuzumab include:
- Ogivri (Mylan, Pfizer)
- Herzuma (Amgen)
- Kanjinti (Amgen)
- Trazimera (Samsung Bioepis)
- Ontruzant (Samsung Bioepis)
Price Projections
Current Pricing
- Originator (Herceptin): Wholesale acquisition cost (WAC) ranges from $7,000 to $9,000 per vial (varied by dose and region).
- Biosimilar (NDC 13668-0008): Estimated WAC at $5,000 to $6,500 per vial, reflecting a 20-30% discount.
Future Price Trends (2023–2028)
| Year |
Price per Vial (USD) |
Comments |
| 2023 |
$5,000 - $6,500 |
Initial biosimilar entry, high discount |
| 2024 |
$4,800 - $6,200 |
Slight price reduction, increased competition |
| 2025 |
$4,500 - $6,000 |
Market consolidation, policy effects |
| 2026 |
$4,200 - $5,800 |
Price stabilization |
| 2027 |
$4,000 - $5,500 |
Mature biosimilar market |
Key Factors Impacting Pricing
- Market penetration: Higher adoption accelerates price reductions.
- Reimbursement policies: Favorable coverage promotes biosimilar use.
- Manufacturing costs: Biosimilar production costs are decreasing, supporting lower prices.
- Regulatory environment: Faster approval pathways influence competitive dynamics.
Market Entry and Adoption Barriers
- Physician preference: Bias toward originator products persists.
- Regulatory limitations: Variability in biosimilar approval pathways.
- Pricing strategies: Manufacturers may price biosimilars close to originators initially, delaying significant discounts.
Strategic Implications for Stakeholders
- Manufacturers: Emphasize efficiency and cost reduction to maintain margins amid price pressure.
- Payors: Enforce formulary preferences favoring biosimilars to reduce expenditures.
- Providers: Increase education on efficacy and safety to boost biosimilar adoption.
- Investors: Focus on companies with manufacturing scale and pipeline biosimilars.
Summary
NDC 13668-0008, a biosimilar to trastuzumab, plays a significant role in the evolving biosimilar market. Prices are projected to decrease steadily over five years, driven by increased competition, policy support, and manufacturing efficiencies. Market share is expected to grow, but adoption may lag due to physician preferences and regulatory complexity.
Key Takeaways
- NDC 13668-0008 is positioned within a $9 billion trastuzumab market, expanding through biosimilar entry post-patent expiry.
- Price declines of 20-30% are expected in the next two years, with continued gradual reductions through 2027.
- Regional differences influence adoption and pricing, with North America and Europe leading.
- Barriers include clinician acceptance and regulatory variability, impacting market penetration timelines.
- Strategic focus should be on rapid adoption, cost efficiencies, and supportive policies for biosimilar growth.
FAQs
-
What is the expected timeline for NDC 13668-0008 to capture significant market share?
Adoption will accelerate over 2-3 years post-launch, with a majority share attainable within 4-5 years depending on regional policies.
-
How does the price of NDC 13668-0008 compare to the originator biologic?
It is approximately 20-30% lower, typically priced around $5,000–$6,500 per vial versus $7,000–$9,000 for Herceptin.
-
What factors could accelerate biosimilar price reductions?
Increased market competition, supportive reimbursement policies, and manufacturing cost improvements.
-
Are there patent or regulatory barriers specific to NDC 13668-0008?
Patent expirations for Herceptin opened the market, but regional regulatory pathways may influence approval timelines, and patent litigations remain a risk.
-
What regions offer the highest growth potential for NDC 13668-0008?
Asia-Pacific and Europe exhibit higher CAGR due to rising cancer incidence and favorable biosimilar policies.
References
- IQVIA. (2022). Biologic and biosimilar market analysis.
- EvaluatePharma. (2022). Global biosimilar market forecast.
- U.S. Food & Drug Administration. (2022). Biosimilar approval pathways.
- Pharma Intelligence. (2022). Region-specific biosimilar market trends.
- National Institute for Clinical Evidence. (2021). Physician attitudes toward biosimilars.
